Berotec N 100mcg aerosol Fenoterol

Medicinical form: Dosed aerosol.

Basic physical and chemical properties: transparent, colorless, slightly yellowish or slightly brownish liquid, free from suspended particles.

Pharmacological group: Drugs used in obstructive respiratory diseases. Selective agonists of beta-2-adrenergic receptors.

ATX code R03А С04.

Composition:

Active ingredient: Fenoterol

1 dose contains 100 mcg fenoterol hydrobromide; excipients: propellant: tetrafluoroethane (HFA 134a), citric acid, purified water, ethanol.

Indications:

Symptomatic treatment of acute asthma attacks.

Prevention of exercise-induced asthma.

Symptomatic treatment of allergic and non-allergic bronchial asthma and / or other conditions with reversible airway obstruction, such as chronic obstructive bronchitis with and without emphysema.

Long-term therapy should always be accompanied by concomitant anti-inflammatory therapy.

Contraindications:

Hypersensitivity to fenoterol hydrobromide or to excipients of metered aerosol (see section “Composition”).

Hypertrophic obstructive cardiomyopathy.

Tachyarrhythmia.

Method of administration and dosage:

The dose should be selected depending on the nature and severity of the disease.

For adults and children over 6 years of age, the following dosage regimens are recommended.

For the relief of an acute attack of bronchial asthma and an attack of shortness of breath, inhalation of a dose of 100 μg of fenoterol hydrobromide (1 inhalation) is recommended.

In general, with an acute attack of shortness of breath, 1 inhalation is sufficient to quickly facilitate breathing. If breathing does not improve significantly within 5 minutes after using the inhalation, a second inhalation can be given. If there is no effect after 2 inhalations, it may be necessary to use additional inhalations. In such cases, the patient should immediately consult a doctor (see section “Peculiarities of use”).

If it is considered necessary to use beta-2-sympathomimetics for long-term treatment, the recommended dose is 1-2 inhalations of Berotek N 3-4 times a day. In general, the time and dose of each use of the drug Berotek N should be determined by the frequency and severity of shortness of breath (by symptoms). Treatment should be accompanied by anti-inflammatory therapy, especially in bronchial asthma. There should be an interval of at least 3 hours between inhalations. The total daily dose should not exceed 8 inhalations, and the maximum single dose should not exceed 4 inhalations, since the highest dose does not add therapeutic benefits in general, but can cause severe side effects.

For specific prophylaxis of exercise-induced asthma, or when contact with an allergen is expected, 1-2 inhalations of Berotek N are used, if possible, for 10-5 minutes before the alleged incident.

For the relief of an acute attack of bronchial asthma and an attack of shortness of breath, inhalation of a dose of 100 μg of fenoterol hydrobromide (1 inhalation) is recommended.

For long-term treatment or prevention of an attack, 100 μg (1 inhalation) of fenoterol hydrobromide should be used 4 times a day. The time and dose of each application of the drug Berotek N should be determined by the frequency and severity of shortness of breath (by symptoms). Treatment should be accompanied by anti-inflammatory therapy, especially in bronchial asthma. There should be an interval of at least 3 hours between inhalations. The total daily dose should not exceed 4 inhalations, and the maximum single dose should not exceed 2 inhalations, since the highest dose does not add therapeutic benefits in general, but can cause severe side effects.

For specific prophylaxis of exercise-induced asthma or when exposure to an allergen is expected, use 100 mcg (1 inhalation) of fenoterol hydrobromide, if possible from 10-15 minutes prior to the anticipated incident.

ATTENTION. If there is no significant improvement or if the condition worsens, despite the prescribed treatment, you should consult with your doctor to revise the treatment plan, a possible combination with the use of other drugs (anti-inflammatory drugs such as corticosteroids, or bronchodilators such as theophylline) or change the dosage. Sudden and progressive worsening of asthma symptoms can be life threatening. In this case, immediate medical attention is needed. It is dangerous to use doses much higher than the recommended ones.

Several cases of increased risk of serious complications of the underlying disease, as well as deaths, have been reported with prolonged treatment of bronchial asthma with excessively high doses of inhaled beta-2-sympathomimetics without sufficient anti-inflammatory therapy. The causal relationship has not been fully explained. However, inadequate anti-inflammatory therapy seems to play a critical role in this.

Shelf life:3 years.

Storage conditions:
Store in its original packaging at a temperature not exceeding 25 °C.

Produced in Germany

Antiallergic